Stock Market News
Alliance Pharma sells Chinese rights to Forceval for £2.9m
AIM-listed Alliance Pharma said on Tuesday that it has agreed to sell its 60% interest in its non-core business, Unigreg, to joint venture partner Pacific Glory Development for £2.9m.
Unigreg owns the rights to Forceval, a micro-nutrient supplement used in pregnancy, in China and some nearby territories. Alliance will continue to market the Forceval brand in the UK.
As well as the £2.9m cash consideration, all outstanding shareholder loans made by the group to Unigreg, totalling £1.5m, will be repaid in full as a condition of completion. Alliance said the initial cash receipts of £3.9m will be used to reduce its current bank debt.
The specialty pharmaceutical group said China, which it has had an economic interest in through Unigreg since 2007, remains a key territory. Last year it established its own affiliate in Shanghai to market a range of child nutraceutical products sold in China and to maintain close links to the Shanghai-based distributor of Kelo-cote in China, the product's largest market.
Numis, which rates the stock at 'buy', said: "We view today's news as a sensible divestment in order to focus Alliance's China operations on its direct channel and through its Kelo-cote partnership and it also provides a helpful cash flow into the business.
"Alliance trades at 16x 2018E EPS for 12% 2018-20E CAGR EPS, which we continue to view as attractive."
At 0944 BST, the shares were down 0.1% to 76.50p.
Unigreg owns the rights to Forceval, a micro-nutrient supplement used in pregnancy, in China and some nearby territories. Alliance will continue to market the Forceval brand in the UK.
As well as the £2.9m cash consideration, all outstanding shareholder loans made by the group to Unigreg, totalling £1.5m, will be repaid in full as a condition of completion. Alliance said the initial cash receipts of £3.9m will be used to reduce its current bank debt.
The specialty pharmaceutical group said China, which it has had an economic interest in through Unigreg since 2007, remains a key territory. Last year it established its own affiliate in Shanghai to market a range of child nutraceutical products sold in China and to maintain close links to the Shanghai-based distributor of Kelo-cote in China, the product's largest market.
Numis, which rates the stock at 'buy', said: "We view today's news as a sensible divestment in order to focus Alliance's China operations on its direct channel and through its Kelo-cote partnership and it also provides a helpful cash flow into the business.
"Alliance trades at 16x 2018E EPS for 12% 2018-20E CAGR EPS, which we continue to view as attractive."
At 0944 BST, the shares were down 0.1% to 76.50p.
Related share prices |
---|
Alliance Pharma (APH) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price